Accessibility Menu
Medexus Pharmaceuticals logo

Medexus Pharmaceuticals(OTC) MEDXF

Market Cap$110.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-5%
5 Year-42%
1 Year+69%
1 Month+20%
$3.50
-1.46%
-0.05Today
Medexus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 3.502026-07-27
Medexus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.78%USD 3.602026-07-20
1 month+20.23%USD 2.912026-06-26
3 month+21.82%USD 2.872026-04-28
Year to date+66.18%USD 2.112025-12-31
1 year+69.16%USD 2.072025-07-25
3 year+122.93%USD 1.572023-07-28
5 year-41.96%USD 6.032021-07-28
Since inception-5.42%USD 3.702017-11-27

Medexus Pharmaceuticals Financials at a Glance

Market Cap

$110.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$99.33M

Net Income (TTM)

-$2.39M

EPS (TTM)

-$0.07

P/E Ratio

-46.79

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$3.50

Volume

11,674

Open

$3.58

Previous Close

$3.50

Daily Range

$3.49 - $3.58

52-Week Range

$1.80 - $3.69

Estimated Earnings Date

Aug 18, 2026

MEDXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. is a specialized pharmaceutical firm operating in Canada and the United States. The company focuses on critical therapeutic areas, including oncology, hematology, rheumatology, autoimmune disorders, and allergies.

Products and Services
  • Rasuvo and Metoject for rheumatoid arthritis management
  • IXINITY, a therapy for Hemophilia B
  • Rupall, a prescription medication for allergies
Growth Outlook
  • Recent quarterly revenue reached $24.65 million, indicating stable demand
  • Gross profit margin improved to 54.8% in the latest quarter
  • Strong product pipeline supports future revenue growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of $99.4 million
  • Operating income margin of 7.8% in the latest quarter
  • Cash flow from operations was $3.79 million in the most recent quarter
Medexus Pharmaceuticals Inc. has established a diverse product portfolio that addresses significant medical needs. The company's focus on specialized therapies positions it well within the healthcare sector. Recent financial performance shows promising trends, with a notable increase in revenue and gross profit margins. The latest quarterly results reflect a solid operational foundation, with cash flow from operations indicating effective management of resources. As the company continues to innovate and expand its offerings, it remains a noteworthy player in the pharmaceutical industry.
AI Generated • Jul 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

90

CEO

Kenneth d’Entremont

Website

www.medexus.com

Headquarters

Toronto, ON M5C 1C3, CA

MEDXF Financials

Key Financial Metrics (TTM)

Gross Margin

54.78%

Operating Margin

5.62%

Net Income Margin

-2.41%

Return on Equity

-4.64%

Return on Capital

8.19%

Return on Assets

-1.63%

Earnings Yield

-2.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$110.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.66M

Volume

11.67K

Avg. Volume

14.98K

Financials (TTM)

Gross Profit

$54.41M

Operating Income

$5.84M

EBITDA

$12.66M

Operating Cash Flow

$18.87M

Capital Expenditure

-$15.15M

Free Cash Flow

$3.72M

Cash & ST Invst.

$6.52M

Total Debt

$22.26M

Medexus Pharmaceuticals Performance Analysis

Medexus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 108,096,00040.9%
20242024-03-31USD 113,054,0004.6%
20252025-03-31USD 108,332,000-4.2%
20262026-03-31USD 99,332,000-8.3%
Medexus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-0.6%
Q22025-09-300.5%
Q32025-12-312.4%
Q42026-03-31-2.7%
Medexus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD 0.06N/A
20242024-03-31USD -0.01N/A
20252025-03-31USD 0.08N/A
20262026-03-31USD -0.07N/A
Medexus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30181.4%
Q22025-09-30-159.3%
Q32025-12-31126.0%
Q42026-03-31-3396.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$24.65M

-0.4%

Gross Profit

$13.27M

+6.8%

Gross Margin

53.84%

N/A

Market Cap

$110.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.23M

N/A

Employees

90

N/A

Net Income

-$2.68M

-383.7%

EBITDA

$544.00K

-85.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$6.52M

-72.8%

Total Debt

$22.26M

-40.1%

Accounts Receivable

$14.86M

+11.7%

Inventory

$33.30M

-5.6%

Long Term Debt

$20.05M

+10026.8%

Short Term Debt

$2.21M

-94.0%

Return on Assets

-1.63%

N/A

Return on Invested Capital

5.96%

N/A

Free Cash Flow

-$11.22M

-604.5%

Operating Cash Flow

$3.79M

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DBCCFDecibel Cannabis Company Inc.
$0.08-0.82%
VEXTFVext Science, Inc.
$0.18+1.29%
PLNHPlanet 13 Holdings Inc.
$0.12-0.91%
INISRadnostix, Inc.
$0.07+16.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About MEDXF

What is the current price of Medexus Pharmaceuticals?

Medexus Pharmaceuticals is trading at $3.50 per share.

What is the 52-week range for Medexus Pharmaceuticals?

Over the past 52 weeks, Medexus Pharmaceuticals has traded between $1.80 and $3.69.

How much debt does Medexus Pharmaceuticals have?

As of the most recent reporting period, Medexus Pharmaceuticals reported total debt of $22.26M.

How much cash does Medexus Pharmaceuticals have on hand?

Medexus Pharmaceuticals reported $6.52M in cash and cash equivalents in its most recent financial results.

What is Medexus Pharmaceuticals’s dividend yield?

Medexus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services